Novadaq Technologies Inc (NASDAQ:NVDQ) (TSE:NDQ) was downgraded by research analysts at Craig Hallum from a “buy” rating to a “hold” rating in a research note issued to investors on Monday. They currently have a $11.75 price objective on the medical research company’s stock. Craig Hallum’s price objective would indicate a potential downside of 0.42% from the stock’s previous close.

Several other analysts also recently weighed in on the company. Wedbush downgraded Novadaq Technologies from an “outperform” rating to a “neutral” rating in a research report on Monday. Northland Securities restated a “hold” rating and set a $11.75 price objective on shares of Novadaq Technologies in a research report on Monday. Stifel Nicolaus restated a “buy” rating and set a $10.00 price objective on shares of Novadaq Technologies in a research report on Friday, June 2nd. Zacks Investment Research upgraded Novadaq Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, May 9th. Finally, Scotiabank reiterated an “outperform” rating and issued a $18.00 target price on shares of Novadaq Technologies in a research report on Thursday, May 4th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $11.22.

Analyst Recommendations for Novadaq Technologies (NASDAQ:NVDQ)

Novadaq Technologies (NASDAQ NVDQ) opened at 11.80 on Monday. Novadaq Technologies has a one year low of $5.84 and a one year high of $12.74. The company’s market capitalization is $682.06 million. The firm’s 50 day moving average price is $7.31 and its 200-day moving average price is $7.25.

Novadaq Technologies (NASDAQ:NVDQ) (TSE:NDQ) last announced its quarterly earnings data on Wednesday, May 3rd. The medical research company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.03. Novadaq Technologies had a negative return on equity of 49.93% and a negative net margin of 71.97%. The business had revenue of $21.08 million for the quarter, compared to the consensus estimate of $20.12 million. Equities analysts forecast that Novadaq Technologies will post ($0.80) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/06/19/novadaq-technologies-inc-nvdq-rating-lowered-to-hold-at-craig-hallum.html.

Several large investors have recently modified their holdings of NVDQ. Boothbay Fund Management LLC acquired a new stake in Novadaq Technologies during the fourth quarter valued at approximately $118,000. Quantitative Systematic Strategies LLC acquired a new stake in Novadaq Technologies during the first quarter valued at approximately $169,000. State Street Corp boosted its stake in Novadaq Technologies by 4.5% in the fourth quarter. State Street Corp now owns 26,164 shares of the medical research company’s stock valued at $186,000 after buying an additional 1,138 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Novadaq Technologies by 12.9% in the first quarter. Envestnet Asset Management Inc. now owns 25,374 shares of the medical research company’s stock valued at $197,000 after buying an additional 2,898 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Novadaq Technologies by 8.2% in the first quarter. Geode Capital Management LLC now owns 29,004 shares of the medical research company’s stock valued at $225,000 after buying an additional 2,194 shares in the last quarter. 88.25% of the stock is owned by institutional investors.

Novadaq Technologies Company Profile

NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.

Receive News & Ratings for Novadaq Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.